Skip to main content
SpringerLink
Log in

Cardiac Manifestations in Antiphospholipid Syndrome

  • Chapter
Hughes Syndrome

Conclusions

Whether the aPL are cause of these cardiac complications or simply accompany more basic underlying immunological disturbances cannot be assessed from these studies. However, serial screening of aPL in patients who develop these complications will help to assess the prevalence and usefulness of these antibodies in cardiac diseases. Until these studies become available, clinicians should consider a search for aPL in those patients with the previously reported cardiac complications in whom no other etiology could be found.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ziporen L, Goldberg I, Arad M, et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: Immunopathogenic findings in deformed heart valves. Lupus 1996;5:196–205.

    PubMed  CAS  Google Scholar 

  2. Ford PM, Ford SE, Lillicrap DP. Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus. J Rheumatol 1988;15:597–600.

    PubMed  CAS  Google Scholar 

  3. Anderson D, Bell D, Lodge R, Grant E. Recurrent cerebral ischemia and mitral valve vegetation in a patient with lupus anticoagulant. J Rheumatol 1987;14:839–841.

    PubMed  CAS  Google Scholar 

  4. Nihoyannopoulos P, Gomez PM, Joshi J, et al. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990;82:369–375.

    PubMed  CAS  Google Scholar 

  5. Khamashta MA, Cervera R, Asherson RA, et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 1990;335:1541–1544.

    Article  PubMed  CAS  Google Scholar 

  6. Cervera R, Font J, Paré C, et al. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis 1992;51:156–159.

    Article  PubMed  CAS  Google Scholar 

  7. Cervera R, Khamashta MA, Font J, et al. High prevalence of significant heart valve lesions in patients with the ‘primary’ antiphospholipid syndrome. Lupus 1991;1:43–47.

    PubMed  CAS  Google Scholar 

  8. Brenner B, Blumenfeld Z, Markiewicz W, et al. Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol 1991;18:931–936.

    PubMed  CAS  Google Scholar 

  9. Galve E, Ordi J, Barquinero J, et al. Valvular heart disease in the primary antiphospholipid syndrome. Ann Intern Med 1992;116:293–298.

    PubMed  CAS  Google Scholar 

  10. Nesher G, Ilani J, Rosenmann D, et al. Valvular dysfunction in antiphospholipid syndrome: Prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997;27:27–35.

    Article  PubMed  CAS  Google Scholar 

  11. Metz D, Jolly D, Graciet-Richard J, et al. Prevalence of valvular involvement in systemic lupus erythematosus and association with antiphospholipid syndrome: a matched echocardiographic study. Cardiology 1994;85:129–136.

    Article  PubMed  CAS  Google Scholar 

  12. Roldan CA, Shively BK, Lau CC, et al. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol 1992;20:1127–1134.

    Article  PubMed  CAS  Google Scholar 

  13. Leung W-H, Wong K-L, Lau C-P, et al. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990;89:411–419.

    Article  PubMed  CAS  Google Scholar 

  14. Amital H, Langevitz P, Levy Y, et al. Valvular deposition of antiphospholipid antibodies in the antiphospholipid syndrome: a clue to the origin of the disease. Clin Exp Rheumatol 1999;17:99–102.

    PubMed  CAS  Google Scholar 

  15. García-Torres R, Amigo MC, de la Rossa A, et al. Valvular heart disease in primary antiphospholipid syndrome: clinical and morphological findings. Lupus 1996;5:56–61.

    PubMed  Google Scholar 

  16. Hojnik M, George J, Ziporen L, et al. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996;93:1579–1587.

    PubMed  CAS  Google Scholar 

  17. Asherson RA, Gibson DG, Evans DW, et al. Diagnostic and therapeutic problems in two patients with antiphospholipid antibodies, heart valve lesions and transient ischaemic attacks. Ann Rheum Dis 1988;47:947–953.

    PubMed  CAS  Google Scholar 

  18. Font J, Cervera R, Paré C, et al. Haemodynamically significant non-infective verrucous endocarditis in a patient with ‘primary’ antiphospholipid syndrome. Br J Rheumatol 1991;30:305–307.

    PubMed  CAS  Google Scholar 

  19. Asherson RA, Tikly M, Staub H, et al. Infective endocarditis, rheumatoid factor, and anticardiolipin antibodies. Ann Rheum Dis 1990;49:107–108.

    PubMed  CAS  Google Scholar 

  20. Young SM, Fisher M, Sigsbee A, et al. Cardiogenic brain embolism and lupus anticoagulant. Ann Neurol 1989;26:390–392.

    Article  PubMed  CAS  Google Scholar 

  21. D’Alton JG, Preston DN, Bormanis J, et al. Multiple transient ischemic attacks, lupus anticoagulant and verrucous endocarditis. Stroke 1985;16:512–514.

    PubMed  CAS  Google Scholar 

  22. Levine SR, Kim S, Deegan MJ, et al. Ischemic stroke associated with anticardiolipin antibodies. Stroke 1987;18:1101–1106.

    PubMed  CAS  Google Scholar 

  23. The Antiphospholipid Antibodies in Stroke Study Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischaemia. Stroke 1990;21:1268–1273.

    Google Scholar 

  24. Font J, Pérez-Villa F, Cervera R, et al. Antiphospholipid antibodies and severe valvular regurgitation in patients with systemic lupus erythematosus. A long-term follow-up echocardiographic study. Arthritis Rheum 1999;42(suppl):S366.

    Google Scholar 

  25. Espinola-Zavaleta N, Vargas-Barron J, Colmenares-Galvis T, et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J 1999;137:973–978.

    Article  PubMed  CAS  Google Scholar 

  26. Erkan D, Sammaritano L, Lockshin MD. Management of the difficult aspects of antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y, eds. Antiphospholipid syndrome II. Autoimmune thrombosis. Amsterdam: Elsevier; 2002:395–407.

    Google Scholar 

  27. Lockshin MD, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 2003;12:518–523.

    Article  PubMed  CAS  Google Scholar 

  28. Manzi S, Meilhan EN, Rairie J, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus comparison with the Framingham Study. Am J Epidemiol 1997;145:408–415.

    PubMed  CAS  Google Scholar 

  29. Petri M, Lakatta C, Magder L, et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994;96:254–259.

    Article  PubMed  CAS  Google Scholar 

  30. Karrar A, Sequeira W, Block JA. Coronary artery disease in systemic lupus erythematosus: a review of the literature. Semin Arthritis Rheum 2001;30:436–443.

    Article  PubMed  CAS  Google Scholar 

  31. Asherson RA, Cervera R. Antiphospholipid antibodies and the heart. Lessons and pitfalls for the cardiologist. Circulation 1991;84:920–923.

    PubMed  CAS  Google Scholar 

  32. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000;9:170–175.

    Article  PubMed  CAS  Google Scholar 

  33. Asherson RA, Harris EN, Gharavi AE, et al. Myocardial infarction in SLE and ‘lupus-like’ disease. Arthritis Rheum 1985;29:1292–1293.

    Google Scholar 

  34. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019–1027.

    Article  PubMed  Google Scholar 

  35. Vaarala O, Mänttäri M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23–27.

    PubMed  CAS  Google Scholar 

  36. Puurunen M, Manttari M, Manninen V, et al. Antibodies to oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605–2609.

    Article  PubMed  CAS  Google Scholar 

  37. Iuliano L, Pratico D, Ferro D, et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997;90:3931–3935.

    PubMed  CAS  Google Scholar 

  38. Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus 1998;7(suppl 2):132–134.

    Google Scholar 

  39. Hamsten A, Norberg R, Bjorkholm M, et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986;1:113–116.

    Article  PubMed  CAS  Google Scholar 

  40. Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997;28:1660–1665.

    PubMed  CAS  Google Scholar 

  41. Adler Y, Finkelstein Y, Zandeman-Goddard G, et al. The presence of antiphospholipid antibodies in acute myocardial infarction. Lupus 1995;4:309–313.

    PubMed  CAS  Google Scholar 

  42. Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients: a controlled prospective study. Am J Med 1996;171:381–386.

    Article  Google Scholar 

  43. Espinosa G, Cervera R, Font J, et al. Cardiac and pulmonary manifestations in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y, eds. The antiphospholipid syndrome II. Autoimmune thrombosis. Amsterdam: Elsevier; 2002:169–188.

    Google Scholar 

  44. Wu R, Nityanand S, Berglund L, et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997;17:3159–3163.

    PubMed  CAS  Google Scholar 

  45. Sletnes KE, Smith P, Abdelnoor M, et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992;339:451–453.

    Article  PubMed  CAS  Google Scholar 

  46. Phadke KV, Phillips RA, Clarke DT, et al. Anticardiolipin antibodies in ischaemic heart disease: marker or myth? Br Heart J 1993;69:391–394.

    PubMed  CAS  Google Scholar 

  47. Bili A, Moss AJ, Francis CW, et al. Anticardiolipin antibodies and recurrent coronary events. A prospective study of 1150 patients. Circulation 2000;102:1258–1263.

    PubMed  CAS  Google Scholar 

  48. De Caterina R, D’Ascanio A, Mazzone A, et al. Prevalence of anticardiolipin antibodies in coronary artery disease. Am J Cardiol 1989;65:922–923.

    Article  Google Scholar 

  49. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996;5:442–447.

    PubMed  CAS  Google Scholar 

  50. Baker WF Jr, Bick RL. Antiphospholipid antibodies in coronary artery disease: a review. Semin Thromb Hemost 1994;20:27–45.

    PubMed  Google Scholar 

  51. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The ‘primary’ antiphospholipid syndrome: Major clinical and serological features. Medicine (Baltimore) 1989;68:366–374.

    PubMed  CAS  Google Scholar 

  52. Díaz MN, Becker RC. Anticardiolipin antibodies in patients with unstable angina. Cardiology 1994;84:380–384.

    Article  PubMed  Google Scholar 

  53. Farsi A, Domeneghetti MP, Fedi S, et al. High prevalence of anti-beta2-glycoprotein I antibodies in patients with ischemic heart disease. Autoimmunity 1999;30:93–98.

    Article  PubMed  CAS  Google Scholar 

  54. Bick RL, Ismail Y, Baker WF Jr. Coagulation abnormalities in patients with precocious coronary artery thrombosis and patients failing coronary artery bypass grafting and percutaneous transcoronary angioplasty. Semin Thromb Hemost 1993;19:411–417.

    Google Scholar 

  55. Gavaghan TP, Krilis SA, Daggard GE, et al. Anticardiolipin antibodies and occlusion of coronary bypass grafts. Lancet 1987;2:977–978.

    Article  PubMed  CAS  Google Scholar 

  56. Morton KE, Gavaghan TP, Krilis SA, et al. Coronary artery bypass graft failure: an autoimmune phenomenon? Lancet 1986;2:1353–1356.

    Article  PubMed  CAS  Google Scholar 

  57. Eber B, Schumacher M, Auer-Grumbach P, et al. Increased IgM anticardiolipin antibodies in patients with restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:1255–1258.

    Article  PubMed  CAS  Google Scholar 

  58. Chambers JD, Haire WD, Deligonul U. Multiple early percutaneous transluminal coronary angioplasty failures related to lupus anticoagulant. Am Heart J 1996;132:189–190.

    Article  PubMed  Google Scholar 

  59. Ludia C, Domenico P, Monia C, et al. Antiphospholipid antibodies: a new risk factor for restenosis after percutaneous transluminal coronary angioplasty? Autoimmunity 1998;27:141–148.

    PubMed  CAS  Google Scholar 

  60. Takeuchi S, Obayashi T, Toyama J. Primary antiphospholipid syndrome with acute myocardial infarction recanalised by PTCA. Heart 1998;79:96–98.

    PubMed  CAS  Google Scholar 

  61. Jankowski M, Didek D, Dubiel JS, et al. Successful coronary stent implantation in a patient with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1998;9:753–756.

    PubMed  CAS  Google Scholar 

  62. Umesan CV, Kapoor A, Nityanand S, et al. Recurrent acute coronary events in a patient with primary antiphospholipid syndrome: successful management with intracoronary stenting. Int J Cardiol 1999;71:99–102.

    Article  PubMed  CAS  Google Scholar 

  63. Lubbe WF, Asherson RA. Intracardiac thrombus in systematic lupus erythematosus associated with lupus anticoagulant. Arthritis Rheum 1988;31:1453–1454.

    PubMed  CAS  Google Scholar 

  64. Leventhal LJ, Borofsky MA, Bergey PD, Schumacher HR Jr. Antiphospholipid antibody syndrome with right atrial thrombosis mimicking an atrial myxoma. Am J Med 1989;87:111–113.

    Article  PubMed  CAS  Google Scholar 

  65. Brown JH, Doherty CC, Allan DC, Morton P. Fatal cardiac due to myocardial microthrombi in systemic lupus erythematosus. Br Med J 1989;298:525.

    Article  CAS  Google Scholar 

  66. Murphy JJ, Leach IA. Findings at necropsy in the heart of a patient with anticardiolipin syndrome. Br Heart J 1989;62:61–64.

    PubMed  CAS  Google Scholar 

  67. Kattwinkel N, Villanueva AG, Labib SB, Aretz T, Walek JW, Burns DL et al. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome. Ann Intern Med 1992;116:974–976.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain

    Josep Font MD, PhD, FRCP & Ricard Cervera MD, PhD, FRCP

Authors
  1. Josep Font MD, PhD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ricard Cervera MD, PhD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lupus Research Unit, St Thomas’ Hospital, London, UK

    M. A. Khamashta MD, FRCP, PhD (Deputy Head) (Deputy Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Font, J., Cervera, R. (2006). Cardiac Manifestations in Antiphospholipid Syndrome. In: Khamashta, M.A. (eds) Hughes Syndrome. Springer, London. https://doi.org/10.1007/1-84628-009-5_5

Download citation

  • DOI: https://doi.org/10.1007/1-84628-009-5_5

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-873-2

  • Online ISBN: 978-1-84628-009-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation